AI assistant
Amphastar Pharmaceuticals, Inc. — Director's Dealing 2019
Jul 13, 2019
10216_dirs_2019-07-12_f043e287-896f-41b3-b007-e86a6d1759d8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Amphastar Pharmaceuticals, Inc. (AMPH)
CIK: 0001297184
Period of Report: 2019-07-10
Reporting Person: Shandell Jason B. (Director, President and General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-10 | Common Stock | S | 6615 | $20.3074 | Disposed | 154443 | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $20.42 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: Includes 1,111 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2019.